Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report first quarter 2026 financial results on Monday, May 4, 2026, after the close of the U.S. financial markets. The Company will ...
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Travere Therapeutics, Inc.
An established sales force and payer authorization criteria will fuel a fast launch for Travere Therapeutics’ Filspari in its ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Travere Therapeutics rated a Buy after Filspari’s FDA approval for FSGS—only therapy available. Read TVTX's valuation upside, ...
Focused on rare disease therapies, this biotech firm reported a notable insider sale amid a year of substantial share price ...
Travere Therapeutics (TVTX) stock and Ligand Pharmaceuticals (LGND) stock gain on FDA label expansion for Filspari. Read more ...
With the path to blockbusterland now in sight, Travere Therapeutics is ready to hit the ground running after Monday’s ...
The FDA has greenlit Travere Therapeutics’ Filspari as the only available treatment for focal segmental glomerulosclerosis ...
Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare ...
Pharmaceutical Technology on MSN
Travere Therapeutics gains FDA approval for sparsentan in FSGS
In the Phase III DUPLEX Study, Filspari reduced proteinuria by 46% and irbesartan by 30% over 108 weeks.
Full FDA approval establishes sparsentan as the first approved therapy for FSGS, addressing a longstanding reliance on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results